Chapter - 7

Herbal Plant Alternatives for the Management of Chronic Inflammatory Disorders

Vidhan Chand Bala, Asheesh Kumar Gupta, Amit Kumar, Sunil Kumar Tiwari and Sushil Kumar

Abstract

Chronic inflammatory disorders, including rheumatoid arthritis, inflammatory bowel disease, asthma, psoriasis, and type 2 diabetes are characterized by persistent immune dysregulation driven by cytokines like TNF-α, IL-1β, and IL-6, leading to progressive tissue damage and systemic complications. Conventional therapies such as NSAIDs, corticosteroids, and biologics alleviate symptoms but are associated with serious side effects and suboptimal remission rates. Increased interest in the therapeutic potential of medicinal plants and their bioactive compounds, commonly used in traditional medicine practices like Ayurveda and Traditional Chinese Medicine. Compounds such as curcumin (turmeric), boswellic acids (frankincense), gingerols (ginger), resveratrol (grape), and quercetin (onions, apples) modulate inflammatory pathways, particularly NF-κB, MAPK, and cytokine cascades, while enhancing antioxidant defenses. These agents demonstrate efficacy in preclinical models and emerging clinical studies, reducing inflammation across diverse conditions. The multi-target mechanisms of phytochemicals offer advantages over single-target drugs, potentially augmenting existing therapies and minimizing adverse effects. Additionally, combining curcumin with piperine improves how well the body absorbs curcumin and enhances treatment results. While further clinical trials are warranted, integrating herbal alternatives into modern management strategies holds promise for safer, long-term control of chronic inflammatory diseases.

Keywords: Chronic inflammatory disorders, herbal medicine, phytochemicals, anti-inflammatory agents

1. Introduction

Chronic inflammatory disorders such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD, including Crohn's disease and ulcerative

colitis), asthma, psoriasis, and type 2 diabetes are characterized by prolonged, dysregulated immune responses and elevated pro-inflammatory mediators (e.g. TNF-α, IL-1β, IL-6) that drive tissue damage and systemic complications [1, 2]. In RA and psoriasis, NF-κB and MAPK signaling cause joint and skin inflammation; in inflammatory bowel disease (IBD), it results in intestinal ulceration; and in conditions like type 2 diabetes, it leads to insulin resistance and vascular damage [3]. Standard treatments aim to suppress inflammation (e.g. NSAIDs, corticosteroids, disease-modifying antirheumatic drugs, biologics), but these often have serious limitations. For example, chronic NSAID use can cause gastrointestinal ulceration and bleeding in ~2-4% of patients per year and raises cardiovascular risk [4]. Long-term glucocorticoids (steroids) powerfully reduce inflammation but induce immunosuppression, osteoporosis (up to 40% of chronic users develop fractures), metabolic syndrome, and infection risk. Biologic anti-cytokine therapies (anti-TNF, IL-6 inhibitors) improve outcomes but are costly and increase susceptibility to infection and malignancy. Moreover, remission rates remain suboptimal (often <50% in RA) and many patients are refractory to existing drugs [5]. These limitations (and the desire for safer long-term control) have spurred interest in complementary strategies. In particular, numerous medicinal plants used in Traditional Chinese Medicine (TCM), Ayurveda, and Western herbal traditions contain bioactive phytochemicals with anti-inflammatory and immunomodulatory effects. Such plant-based therapies may modulate multiple inflammatory pathways simultaneously and potentially augment conventional treatment while lowering side effects [6, 7].

2. Beneficial herbal plants in inflammatory disorders

Traditional medical systems worldwide recognize many anti-inflammatory plants [8]. Table 1 provides a list of selected herbal anti-inflammatory plants, their active compounds, and the disorders they target [9]. Notable herbs include *Curcuma longa* (turmeric), whose curcuminoids (e.g. curcumin) inhibit NF-κB, COX-2 and MAPK signaling; *Boswellia serrata* (Indian frankincense), whose boswellic acids block 5-lipoxygenase (leukotriene synthesis) and suppress TNF-α/IL-1β release; *Zingiber officinale* (ginger), whose gingerols/shogaols inhibit Akt and NF-κB pathways to reduce IL-6, TNF-α and other cytokines; *Camellia sinensis* (green tea), whose EGCG and catechins inhibit TLR4/NF-κB signaling and oxidative stress; *Oenothera biennis* (evening primrose), containing gamma-linolenic acid, which downregulates pro-inflammatory eicosanoids; *Procumbens harpagophytum* (devil's claw), whose harpagoside reduces TNF-α and COX-2 expression;

Salix alba (white willow), a source of salicin (a natural COX inhibitor); *Quercus alba* (oak) and other quercetin-rich foods (onions, apples), which are potent antioxidants and inhibit histamine and cytokine release; and Vitis vinifera (grape) resveratrol, which activates SIRT1 and suppresses NF-κB-mediated inflammation [8, 9].

Herbal traditions highlight additional examples: TCM uses *Huang Lian* (Coptis, berberine alkaloids) and *Huang Qin* (Scutellaria, baicalin) for their anti-TNF and antioxidant effects; *Gan Cao* (licorice root) provides glycyrrhizin, which modulates cortisol metabolism and immune signaling. Ayurveda employs *Ashwagandha* (Withania, withanolides), *Tulsi* (Ocimum sanctum, ursolic and oleanolic acids), *Guggul* (Commiphora mukul, guggulsterones), and *Triphala* (a polyherbal formulation) to reduce systemic inflammation and improve metabolic balance [10, 11]. Western herbal medicine incorporates Boswellia and turmeric, as well as chamomile (apigenin) and sage, rosemary (carnosic acid) all of which exhibit anti-inflammatory and antioxidant actions. Overall, compounds like polyphenols, flavonoids, carotenoids, and alkaloids from plants are recognized for their ability to reduce inflammation [12].

Table 1: Summarizes herbal plants with anti-inflammatory properties, their active components, and associated target disorders

SL. No.	Herb (Common Name)	Active Compound(s)	Principal Mechanisms	Target Disorders
1.	*Curcuma longa* (Turmeric)	Curcuminoids (curcumin, demethoxycurcumin)	Inhibits NF-κB, MAPK, COX-2; scavenges ROS	RA, IBD, psoriasis, metabolic syndrome
2.	*Boswellia serrata* (Frankincense)	Boswellic acids (AKBA, β-boswellic acid)	Inhibits 5-LOX (leukotrienes), COX; suppresses TNF-α, IL-1β	RA, Crohn's disease, asthma
3.	*Zingiber officinale* (Ginger)	Gingerols (6-gingerol), shogaols	Inhibits NF-κB, Akt pathways; reduces IL-6, TNF-α	RA, IBD, osteoarthritis, nausea
4.	*Camellia sinensis* (Green tea)	EGCG (-)-epigallocatechin-3-gallate	Inhibits TLR4/NF-κB, AP-1; upregulates Nrf2-antioxidant pathways	IBD, arthritis, metabolic syndrome
5.	*Salix alba* (White willow)	Salicin (precursor to salicylic acid)	COX inhibitor; reduces prostaglandins	Rheumatic pain, inflammation
6.	*Harpagophytum procumbens*	Harpagoside	Reduces TNF-α, IL-1β, COX-2	Arthritis, low back pain

	(Devil's claw)			
7.	*Ginkgo biloba* (Ginkgo)	Flavonoids (kaempferol, quercetin), terpenoids	Antioxidant; inhibits platelet-activating factor (PAF)	Peripheral vascular disease, neuroinflammation
8.	*Tinospora cordifolia* (Guduchi)	Alkaloids, diterpenoids (cordifolioside)	Modulates macrophage cytokines	IBD, RA (as adjuvant)
9.	*Commiphora mukul* (Guggul)	Guggulsterone (steroid)**	Modulates NF-κB; lipid-lowering	Dyslipidemia, inflammation
10.	*Piper nigrum* (Black pepper)	Piperine	Inhibits drug metabolism (enhances bioavailability of others)	Often combined with curcumin

Note: RA=rheumatoid arthritis; IBD=inflammatory bowel disease.

In summary, a diverse array of herbs from TCM, Ayurvedic, and Western traditions contain bioactive phytochemicals that target key inflammatory mediators [13]. Many of these compounds act in part by suppressing the NF-κB/MAPK signaling pathways and reducing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), as well as by enhancing endogenous antioxidants. The remainder of this chapter examines selected phytochemicals in detail and their roles in specific inflammatory conditions [14].

3. Management of phytochemicals in different inflammatory disorders

3.1 Curcumin (Turmeric)

Curcumin, the principal curcuminoid of *Curcuma longa*, has been extensively studied for anti-inflammatory effects. It interferes with multiple signaling pathways (NF-κB, MAPK, AP-1, JAK/STAT) to downregulate COX-2, iNOS and pro-inflammatory cytokines. In rheumatoid arthritis, clinical trials and meta-analyses show that curcumin supplementation significantly reduces disease activity scores, C-reactive protein, erythrocyte sedimentation rate, and tender joint counts compared to placebo [10]. Mechanistically, curcumin inhibits the mitogen-activated protein kinase (MAPK/ERK) cascade and AP-1/NF-κB transcription in synovial cells, thereby diminishing IL-1β and TNF-α production. A meta-analysis concluded that curcumin improved pain and clinical indices in RA patients more than conventional control [15].

Curcumin also shows benefit in inflammatory bowel disease. Preclinical colitis models demonstrate that curcumin reduces colonic NF-κB activity and lowers TNF-α and IL-6 levels. In small trials of ulcerative colitis, adjunctive

curcumin (typically 500-2,000 mg/day) has led to higher remission rates and mucosal healing than standard therapy alone. A comprehensive review notes that curcumin effectively treats IBD by suppressing NF-κB, IL-1β and IL-12 signaling [16]. In psoriasis, a T-cell mediated skin inflammation, curcumin inhibits pathogenic cytokines (IL-17, IL-22, IL-23) in models of psoriatic inflammation. Some open-label trials report improvement in plaques with oral curcumin or topical formulations, although evidence is still emerging [17].

Curcumin's metabolic benefits are also noted. By reducing chronic inflammation and oxidative stress, curcumin helps improve insulin sensitivity in type 2 diabetes. A systematic review found that curcumin significantly lowered fasting glucose, HbA1c, triglycerides and high-sensitivity CRP in diabetics. These glycemic improvements are attributed to curcumin's ability to block NF-κB and JNK signaling in adipose and muscle, thus relieving insulin resistance (TNF-α and IL-6 are reduced) [18].

Other conditions: In osteoarthritis, curcumin relieves joint pain and improves function (likely via COX-2 and metalloprotease inhibition). Emerging studies suggest benefit in asthma, where curcumin attenuates airway inflammation and mucus production (suppressing IL-4/IL-13/IgE) in animal models, though human trials are limited. Overall, curcumin's safety profile is excellent (doses up to 6 g/day for weeks show no major toxicity), making it a promising adjunct in many chronic inflammatory disorders [19].

3.2 Resveratrol (Grapes, Berries)

Resveratrol, a stilbene polyphenol found in grape skins, red wine and berries, exerts anti-inflammatory effects via SIRT1 activation and NF-κB inhibition. It downregulates pro-inflammatory mediators (TNF-α, IL-1β) and upregulates antioxidant defenses. In cardiovascular and metabolic syndrome models, resveratrol reduces vascular inflammation and atherogenesis by decreasing adhesion molecules (VCAM-1, ICAM-1) and cytokines. In type 2 diabetes, resveratrol improves insulin signaling partly through anti-inflammatory action and SIRT1-mediated metabolic regulation [20].

In inflammatory bowel disease models, resveratrol suppresses colonic inflammation: it inhibits COX-2 and blocks NF-κB, reducing colitis severity. Quercetin and resveratrol together prevent nuclear translocation of NF-κB by stabilizing IκBα. They also inhibit the NLRP3 inflammasome, lowering IL-1β/IL-18 release. In atherosclerosis and psoriasis, resveratrol's anti-cytokine effects (via GATA-3/Th2 suppression or IL-17 inhibition) have shown efficacy in animal models. Clinical evidence in humans is still developing, but several

trials have indicated modest anti-inflammatory biomarker improvements (e.g. reduced CRP) in metabolic patients. Because resveratrol also enhances regulatory T-cell function and endothelial NO, it may have broad anti-inflammatory benefits, though its poor bioavailability is a limitation [21].

3.3 Quercetin (Flavonoids)

Quercetin is a ubiquitous flavonoid in onions, apples, berries, and herbs (e.g. St. John's wort). It exhibits potent anti-inflammatory and antioxidant properties. Mechanistically, quercetin inhibits NF-κB and AP-1, reduces histamine release, and scavenges free radicals. In skin inflammation (psoriasis, eczema), quercetin suppresses TNF-α and IL-6 production and can improve barrier function. It has also been shown to modulate T-helper cell polarization toward a less inflammatory profile. In IBD models, quercetin protects the intestinal mucosa by downregulating COX-2 and cytokines, thereby reducing bowel damage. In metabolic syndrome, quercetin may improve dyslipidemia and blood pressure partly via its anti-inflammatory effects on the vasculature. Additionally, quercetin enhances antioxidant enzymes (catalase, SOD) through Nrf2 activation [22].

Clinical trials of quercetin supplements have demonstrated reduced markers of inflammation (CRP, IL-6) in allergy and cardiovascular settings. Its strong safety profile makes it attractive as an immune-modulating supplement. While not all chronic conditions have definitive quercetin trials, its broad cytokine-lowering effects (TNF-α, IL-1β) and mast cell stabilization suggest benefits in chronic inflammatory diseases and allergic inflammation [23].

3.4 Boswellic acids (Frankincense)

The pentacyclic triterpenes from *Boswellia serrata* gum resin (particularly acetyl-11-keto-β-boswellic acid, AKBA) are powerful anti-inflammatory agents. They selectively inhibit 5-lipoxygenase (blocking leukotriene synthesis) without the gastrointestinal toxicity of NSAIDs. In rheumatoid arthritis models, boswellic acids suppress leukocyte elastase and NF-κB, leading to reduced TNF-α, IL-1β and IL-6. Clinically, extracts of Boswellia reduce pain and swelling in osteoarthritis and have shown efficacy in collagen-induced arthritis by lowering CRP and improving joint mobility [24].

Importantly, Boswellia has been studied in respiratory and GI inflammation. In asthma models, boswellic acid treatment markedly suppressed Th2-driven airway inflammation: treated mice showed decreased

airway eosinophils, reduced ovalbumin-specific IgE, and lowered IL-4/IL-5/IL-13 cytokines. This effect was linked to inhibition of STAT6 and GATA-3 transcription factors. In fact, early clinical studies in asthmatics reported improved breathing and fewer exacerbations with Boswellia. Similarly, for inflammatory bowel disease, Boswellia extracts have shown benefits in Crohn's disease, reducing diarrhea and pain (likely via leukotriene blockade). A meta-analysis indicated Crohn's patients receiving Boswellia had better clinical response than placebo [25].

Therefore, boswellic acids from Boswellia target various inflammatory pathways, reduce oxidative stress, and have been applied in arthritis, asthma, and inflammatory bowel disease (IBD). Their safety is high (oral doses up to several grams show minimal toxicity) and they are generally well tolerated [26].

3.5 Other notable phytochemicals

- EGCG (Epigallocatechin-3-gallate) from green tea inhibits TLR4/NF-κB and AP-1 signaling, improving airway and metabolic inflammation in models. It also upregulates endogenous antioxidants (via Nrf2).
- Gingerols (from ginger) as noted, inhibit NF-κB and Akt, reducing IL-6/TNF-α; clinically, ginger extracts reduce exercise-induced muscle pain and have shown benefit in osteoarthritis pain.
- Glycyrrhizin (from licorice root) mimics corticosteroids by prolonging endogenous cortisol action and directly inhibits HMGB1, TNF-α and IL-6, which may help in IBD and skin inflammation.
- Andrographolide (Andrographis paniculata) suppresses NF-κB and MAPK; trials in IBD show reduced disease activity.
- Boswellic analogs and derivatives are being formulated (e.g. nanoparticles) to improve bioavailability and target specific disorders more effectively.

Overall, many plant-derived compounds have shown effectiveness in reducing inflammation in various chronic diseases through studies in the lab and with patients. The multi-target nature of phytochemicals often allows concurrent modulation of cytokines, oxidative stress, and immune signaling, contrasting with single-target drugs [27, 28].

4. Combination phytochemical therapy

A key advantage of herbal approaches is synergy: combinations of phytochemicals or whole extracts can interact to enhance anti-inflammatory

effects. For example, co-delivery of curcumin with piperine (from black pepper) increases curcumin's bioavailability and potentiates its effect [29]. In clinical trials of knee osteoarthritis, an herbal formulation containing turmeric (curcumin 300 mg), black pepper and ginger significantly reduced prostaglandin E2 and pain scores over placebo. In another trial, curcumin combined with piperine alleviated symptoms of inflammatory IBS and even improved outcomes in COVID-19 (reflecting its broad immune effects). More generally, systems-biology analyses of multi-herb supplements reveal that diverse phytochemicals can target overlapping pathways for a greater cumulative effect. One recent study used network modeling to show that a multivitamin/mineral supplement's phytochemicals (quercetin, curcumin, ellagic acid, hesperidin, etc.) cooperatively modulated NF-κB and Toll-like receptor pathways, amplifying antioxidant and anti-inflammatory gene expression. Traditional formulations likewise exploit synergy e.g. Triphala (a classic Ayurvedic mixture) combines gallic-acid-rich fruits to synergistically balance gut microbiota and immunity [29].

Synergistic therapy can also involve herb drug combinations. Preclinical data suggest that adding herbal extracts to standard drugs may allow lower drug doses and mitigate toxicity. For instance, combining curcumin with methotrexate in animal arthritis models enhanced efficacy and reduced hepatotoxicity compared to methotrexate alone. Furthermore, intentional polyherbal products (e.g. an Ayurvedic formula "Guggulutikthaka") have been shown to concurrently improve hyperlipidemia, blood sugar and inflammation in metabolic syndrome, illustrating multi-pronged synergy [30].

While true synergy requires careful formulation, even simple combinations (e.g. different botanical extracts) can complement each other by targeting distinct cytokines or cell types. Emerging "phytochemical cocktails" are under study, and early clinical evidence supports that multi-component herbal therapies can produce stronger or broader anti-inflammatory effects than isolated compounds [30].

5. Benefits of herbal plant-based alternatives

Herbal and phytochemical therapies offer several potential benefits over conventional drugs in managing chronic inflammation. One reason herbal therapies have fewer side effects is because they come from natural sources and work well with the body's systems when used appropriately. Most plant compounds are "generally recognized as safe" at dietary doses. For example, long-term studies of Curcuma extract (up to 500 mg twice daily) show good tolerability. Ayurvedic herbs used for IBD reported symptom relief with

"minimal to no side effects (e.g. no increase in infection or occult bleeding)". By contrast, pharmaceuticals like biologics carry significant infection risks, and NSAIDs/steroids damage GI, liver and bone. Many herbs appear to modulate rather than suppress immunity: they often restore balance by dampening pro-inflammatory cytokines while boosting regulatory pathways. For instance, plant polyphenols activate Nrf2 antioxidant responses and enhance IL-10, whereas most drugs blunt immunity globally [31].

Secondly, phytochemicals can help modify chronic diseases over the long term. Chronic inflammation underlies disease progression, and by attenuating the inflammatory milieu, herbs might slow or prevent tissue damage. For example, boswellic acids not only relieve symptoms but also protect against cartilage erosion in arthritis models via antioxidant enzyme induction. Similarly, curcumin's multi-target effects could slow atherosclerosis and insulin resistance by reducing vascular inflammation and oxidative stress over time. Moreover, herbal medicines often affect the gut microbiome favorably e.g. Triphala and curcumin have prebiotic actions which can reprogram immune balance in chronic diseases [32].

Third, herbal therapies provide immune modulation and adaptation**.** Some botanicals (e.g. adaptogenic herbs like Ashwagandha) also support stress resilience and hormonal balance, indirectly improving inflammatory diseases. Many contain antioxidants that protect tissues from damage (e.g. quercetin upregulates catalase/SOD), whereas conventional immunosuppressants often exacerbate oxidative stress [33].

Lastly, combining plant-based treatments with conventional care can provide additional benefits. Preliminary evidence suggests that combining natural compounds with standard drugs can enhance efficacy and reduce adverse effects. For example, adding curcumin to DMARD therapy in RA may allow dose reduction of the DMARD and mitigate its side effects. Indeed, one review noted that plant-derived compounds "possess the ability to augment the effectiveness of current therapies while mitigating their adverse reactions". In all, herbal alternatives offer a complementary, multi-faceted approach: targeting inflammation through diet and botanicals may lead to better long-term control with improved safety [34].

6. Conclusion

Chronic inflammatory disorders present complex therapeutic challenges, and there is growing recognition that single-target drugs often fall short in durable disease control. In this context, medicinal plants and their

phytochemicals from curcumin and resveratrol to boswellic acids and quercetin-provide a rich pharmacopeia of anti-inflammatory agents. These natural compounds engage multiple molecular targets such as NF-κB, MAPK, and inflammasomes, dampening cytokine cascades while enhancing antioxidant defenses. Evidence from laboratory, animal and early clinical studies indicates significant benefits in conditions ranging from RA and IBD to asthma and metabolic syndrome. Importantly, herbal therapies tend to have favorable safety profiles and can modulate the immune response more gently than immunosuppressive drugs. Utilizing a combination of phytochemicals or whole extracts can synergistically enhance therapeutic effects by targeting multiple pathways, potentially reducing side effects and improving overall efficacy.

Moving forward, rigorous clinical trials and integration into practice guidelines will be needed. Advances in formulation (e.g. nanoparticle delivery of curcumin, optimized herb combinations) aim to overcome issues of bioavailability and standardization. In conclusion, a modern integrative approach can effectively utilize herbal medicines as adjuvants or alternatives in the management of inflammatory diseases. By combining traditional wisdom with modern research, we can create comprehensive strategies to enhance the well-being of patients with chronic inflammation and decrease dependence on risky pharmaceuticals.

7. References

1. Vlachos C, Gaitanis G, Katsanos KH, Christodoulou DK, Tsianos E, Bassukas ID. Psoriasis and inflammatory bowel disease: links and risks. Psoriasis (Auckl). 2016;6:73-92.
2. Zhao J, Lu Q, Liu Y, *et al*. TH17 cells in inflammatory bowel disease: cytokines, plasticity, and therapies. J Immunol Res. 2021;2021:1-14.
3. Maier JA, Castiglioni S, Petrelli A, *et al*. Immune-mediated inflammatory diseases and cancer-a dangerous liaison. Front Immunol., 2024, 15.
4. Liang Y, Li Y, Lee C, Yu Z, Chen C, Liang C. Ulcerative colitis: molecular insights and intervention therapy. Mol Biomed, 2024, 5(1).
5. Beyaert R, Beaugerie L, Van Assche G, *et al*. Cancer risk in immune-mediated inflammatory diseases (IMID). Mol Cancer, 2013, 12(1).
6. Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional Chinese medicine: a comparative overview. Evid Based Complement Alternat Med. 2005;2(4):465-473.

7. Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. Foods. 2017;6(10):92.

8. Niranjan A, Singh S, Dhiman M, Tewari SK. Biochemical composition of *Curcuma longa* L. accessions. Anal Lett. 2013;46:1069.

9. Zhou X, Li H, Shi Z, *et al*. Inhibition activity of a traditional Chinese herbal formula Huang-Lian-Jie-Du-Tang and its major components found in its plasma profile on neuraminidase-1. Sci Rep. 2017;7(1):15549.

10. Bommakanti V, Puthenparambil Ajikumar A, Sivi CM, *et al*. An overview of herbal nutraceuticals, their extraction, formulation, therapeutic effects and potential toxicity. Separations. 2023;10:177.

11. Arzani V, Soleimani M, Fritsch T, Jacob UM. Plant polyphenols, terpenes, and terpenoids in oral health. Open Med (Wars). 2025;20(1):20251183.

12. Ansari P, Reberio AD, Ansari NJ, *et al*. Therapeutic potential of medicinal plants and their phytoconstituents in diabetes, cancer, infections, cardiovascular diseases, inflammation and gastrointestinal disorders. Biomedicines. 2025;13:454.

13. Iriti M, Vitalini S, Fico G, Faoro F. Neuroprotective herbs and foods from different traditional medicines and diets. Molecules. 2010;15:3517-3555.

14. Pulido-Moran M, Moreno-Fernandez J, Ramirez-Tortosa C, Ramirez-Tortosa M. Curcumin and health. Molecules. 2016;21(3):264.

15. Maugeri A, Russo C, Patanè GT, *et al*. The inhibition of mitogen-activated protein kinases (MAPKs) and NF-κB underlies the neuroprotective capacity of a cinnamon/curcumin/turmeric spice blend in Aβ-exposed THP-1 cells. Molecules. 2023;28:7949.

16. Vecchi Brumatti L, Marcuzzi A, Tricarico PM, *et al*. Curcumin and inflammatory bowel disease: potential and limits of innovative treatments. Molecules. 2014;19:21127-21153.

17. He Y, Yue Y, Zheng X, *et al*. Curcumin, inflammation, and chronic diseases: how are they linked? Molecules. 2015;20(5):9183-9213.

18. Gu Y, Niu Q, Zhang Q, Zhao Y. Ameliorative effects of curcumin on type 2 diabetes mellitus. Molecules. 2024;29(12):2934.

19. Zuccotti GD, Trabattoni M, Morelli S, *et al*. Immune modulation by lactoferrin and curcumin in children with recurrent respiratory infections. J Biol. Regul. Homeost. Agents. 2008;23:119-123.

20. Meng T, Xiao D, Muhammed A, *et al*. Anti-inflammatory action and mechanisms of resveratrol. Molecules. 2021;26(1):229.
21. Pratelli G, Tamburini B, Carlisi D, *et al*. Foodomics-based approaches shed light on the potential protective effects of polyphenols in inflammatory bowel disease. Int J Mol Sci. 2023;24(19):14619.
22. Carrillo-Martinez EJ, Flores-Hernández FY, Salazar-Montes AM, *et al*. Quercetin, a flavonoid with great pharmacological capacity. Molecules. 2024;29(5):1000.
23. Iddir M, Brito A, Dingeo G, *et al*. Strengthening the immune system and reducing inflammation and oxidative stress through diet and nutrition: considerations during the COVID-19 crisis. Nutrients. 2020;12(6):1562.
24. Siddiqui MZ. Boswellia serrata, a potential anti-inflammatory agent: an overview. Indian J Pharm Sci. 2011;73(3):255-261.
25. Liu Z, Liu X, Sang L, *et al*. Boswellic acid attenuates asthma phenotypes by downregulation of GATA3 via pSTAT6 inhibition in a murine model of asthma. Int J Clin Exp Pathol. 2015;8(1):236-243.
26. Abdel-Tawab M. Considerations to be taken when carrying out medicinal plant research-what we learn from an insight into the IC50 values, bioavailability and clinical efficacy of exemplary anti-inflammatory herbal components. Pharmaceuticals. 2021;14(5):437.
27. Capasso L, De Masi L, Sirignano C, *et al*. Epigallocatechin gallate (EGCG): pharmacological properties, biological activities and therapeutic potential. Molecules. 2025;30(3):654.
28. Rodríguez-Negrete EV, Morales-González Á, Madrigal-Santillán EO, *et al*. Phytochemicals and their usefulness in the maintenance of health. Plants. 2024;13(4):523.
29. Cho HK, Park CG, Lim HB. Construction of a synergy combination model for turmeric (*Curcuma longa* L.) and black pepper (*Piper nigrum* L.) extracts: enhanced anticancer activity against A549 and NCI-H292 human lung cancer cells. Curr Issues Mol Biol. 2024;46(6):5551-5560.
30. Lippert A, Renner B. Herb-drug interaction in inflammatory diseases: review of phytomedicine and herbal supplements. J Clin Med. 2022;11(6):1567.
31. Iyengar P, Godoy-Brewer G, Maniyar I, *et al*. Herbal medicines for the treatment of active ulcerative colitis: a systematic review and meta-analysis. Nutrients. 2024;16(7):934.

32. Ginwala R, Bhavsar R, Chigbu DGI, *et al*. Potential role of flavonoids in treating chronic inflammatory diseases with a special focus on the anti-inflammatory activity of apigenin. Antioxidants. 2019;8(2):35.

33. Kalogerakou T, Antoniadou M. The role of dietary antioxidants, food supplements and functional foods for energy enhancement in healthcare professionals. Antioxidants. 2024;13(12):1508.